|
Medical Advocates Dolutegravir/Abacavir/Lamivudine (Triumeq) |
 |
Main Page New
and NoteworthyJournal
DataNews |
 ARV
Main Page |
Main
New/Newsworthy
|
Home
Page |
Last
Update:
July 26, 2017
 Documents
identified with this icon are in Portable Document Format (PDF) and require the
|
|
Journal Citations |
-
Cost-effectiveness of Dolutegravir/Abacavir/Lamivudine in HIV-1 Treatment-Naïve (TN) Patients in France
Pialoux G, Marcelin AG, Cawston H, et al.
-
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
Orrell C, Hagins DP, Belonosova E, et al
-
Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
Peng S, Tafazzoli A, Dorman E,
et al
-
Bioequivalence of a Dolutegravir, Abacavir and Lamivudine Fixed-Dose Combination Tablet and the Effect of Food.
Weller S, Chen S, Borland J, et al
-
Dolutegravir, abacavir and lamivudine as HIV
therapy.
Fernandez-Montero JV, Barreiro P,
et al
Expert Rev Pharmacoecon Outcomes Res. 2017 Jul 25
Abstract
Lancet HIV. 2017 Jul 17.
Abstract
J Med Econ. 2015 May 1:
Abstract
J Acquir Immune Defic Syndr. 2014 May 4
Abstract
Expert Opin Pharmacother. 2014 May;15(7):1051-7
Abstract
|
News |
|
ARV
Main Page |
Main
New/Newsworthy
|
Home
Page |
|
|